证券代码：300255 证券简称：常山药业 公告编号：2023-40 河北常山生化药业股份有限公司 记载、误导性陈述或重大遗漏。 一、获得补助的基本情况 河北常山生化药业股份有限公司（以下简称"公司"）及子公司于 2023 年 4 月 22 日至 2023 年 8 月 18 日收到与收益相关的政府补助 191.32 万元（占公司最近 一期经审计净利润的 10.92%），公司已实际收到前述相关款项，具体情况如下： | | | | | | | 计 | 与资 | | 是 否 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 获得补 | 提供补 | | 补助 | 补助依据 | 入 | 产相 | | 具 | | 序 | 助的主 | 助的主 | 补助的原 | 金额 | （政府文 | 会 | 关/ | 收到补助 | 有 | | 号 | 体 | 体 | 因或项目 | （万 | 件） | 计 | 收益 | 的时间 | 持 | | | | | | 元） | | 科 | | | | | | | | | | | 目 | 相关 | | 续 | | | ...

证券代码： 300255 证券简称：常山药业 河北常山生化药业股份有限公司投资者关系活动记录表 编号：2023-2 | --- | --- | --- | |----------------|---------------------------|----------------------------------------------------------------| | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 □ | 业绩说明会 | | | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | √ 其他 （河北辖区上市公司 | 2023 年投资者网上集体接待日活动） | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2023 年 5 月 30 日 ( | 周二) 下午 15:00~17:00 | | 地点 | | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开 | | | 上市公司接待人 | 1、财务总监王军 | | | ...

证券代码：300255 证券简称：常山药业 公告编号：2023-24 河北常山生化药业股份有限公司 关于参加河北辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，河北常山生化药业股份有限公司（以下 简称"公司"）将参加由河北证监局、河北省上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年河北辖区上市公司投资者集体接待日活动"，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2023 年 5 月 30 日（周二）15:00-17:00。届时公司高 管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况和可持续发展 等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 河北常山生化药业股份有限公司董事会 2023 年 5 月 25 日 ...

证券代码： 300255 证券简称：常山药业 6、2018 年开始的和以 Kitov 公司合作，至今进展情况怎么， 谢谢回答。 河北常山生化药业股份有限公司投资者关系活动记录表 编号：2023-1 | 投资者关系活动 | 特定对象调研 分析师会议 □ □ | | --- | --- | | 类别 | 媒体采访 业绩说明会 □ √ | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 18 日 (周四) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长高晓东 | | 员姓名 | 2、财务总监王军 | | | 3、董事会秘书刘中英 | | | 4、独立董事曹德英 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问 ...

为使投资者能够进一步了解公司的生产经营等情况，公司定于 2023 年 5 月 18 日（星期四）15:00－17:00 在全景网举办 2022 年度业绩网上说明会，本次年 度业绩说明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互动 平台"（http://rs.p5w.net）参与互动交流。 出席本次说明会的人员有：公司董事长高晓东先生、财务总监王军先生、董 事会秘书刘中英先生、独立董事曹德英先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩网上说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 17 日（星期三）17:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的 问题进行回答。 证券代码：300255 证券简称：常山药业 公告编号：2023-22 河北常山生化药业股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 ...

Financial Performance - Net profit for the period was 558,681.84 CNY, a significant decline from 28,851,938.26 CNY in the previous period, indicating a drop of approximately 98.1%[1] - Basic and diluted earnings per share were both 0.0049 CNY, down from 0.0317 CNY in the previous period, a decrease of about 84.5%[4] - Total comprehensive income attributable to the parent company was 3,861,127.43 CNY, compared to 27,986,439.91 CNY in the previous period, a decrease of about 86.1%[4] - Operating profit for the period was 5,752,668.19 CNY, down from 33,283,613.23 CNY, a decrease of approximately 82.7%[1] - The total profit for the period was 5,744,169.24 CNY, significantly lower than 33,232,129.93 CNY in the previous period, indicating a decline of about 82.7%[1] - Net profit attributable to shareholders of the listed company was ¥4,541,481.07, down 84.68% from ¥29,651,405.14 year-on-year[39] - The net profit after deducting non-recurring gains and losses was -¥5,467,837.78, a decline of 120.01% compared to ¥27,324,880.94 in the previous year[39] - Net profit attributable to the parent company decreased by 84.68% year-on-year, mainly due to reduced sales revenue and increased operating costs[58] Revenue and Costs - Total operating costs for the period were 507,965,611.18 CNY, a decrease from 542,640,735.36 CNY in the previous period, representing a reduction of approximately 6.35%[1] - Cash received from sales of goods and services was 516,943,367.04 CNY, down from 567,261,182.52 CNY, a decline of approximately 8.8%[5] - Total operating revenue for the first quarter was ¥501,924,319.12, a decrease of 12.58% compared to ¥574,179,074.10 in the same period last year[39] - The company's operating revenue decreased by 12.58% year-on-year, primarily due to a decline in the price of heparin raw materials and a drop in sales volume of low molecular weight heparin[58] - Sales expenses decreased by 34.42% compared to the same period last year, mainly due to a decrease in sales revenue[45] Cash Flow - The net cash flow from operating activities was -99,744,873.23, an improvement from -158,674,887.67 in the previous period, indicating a 37% reduction in cash outflow[8] - Cash flow from operating activities increased by 37.14% year-on-year, primarily due to a decrease in cash paid for purchasing goods and receiving services[59] - Cash flow from investing activities decreased by 32.88% year-on-year, mainly due to reduced cash payments for the purchase of fixed assets, intangible assets, and other long-term assets[60] - Cash flow from financing activities decreased by 104.61% year-on-year, primarily due to increased cash payments for debt repayment and decreased cash received from borrowings[60] Assets and Liabilities - The total assets decreased to 5,988,652,588.93 from 6,035,803,472.83, reflecting a decline of approximately 0.78%[13] - Current assets totaled 3,768,013,582.66, down from 3,897,553,391.47, indicating a decrease of about 3.32%[13] - Inventory increased slightly to 2,457,407,774.07 from 2,431,477,436.45, showing a growth of approximately 1.06%[13] - The company's long-term assets increased to 2,220,639,006.27 from 2,138,250,081.36, representing a growth of about 3.84%[13] - The short-term borrowings rose to 1,034,922,546.84 from 971,316,007.39, an increase of approximately 6.5%[13] - Total cash inflow from financing activities was 256,504,238.08, down 42% from 439,130,477.50 in the previous period[8] - The total cash outflow from financing activities was 273,066,875.93, significantly higher than 79,967,821.89 in the previous period, resulting in a net cash flow from financing activities of -16,562,637.85[8] Other Financial Metrics - The company reported a net loss from credit impairment of 1,598,914.09 CNY, contrasting with a gain of 1,408,421.45 CNY in the previous period[1] - Other comprehensive income after tax was -680,353.64 CNY, compared to -1,664,965.23 CNY in the previous period, showing an improvement[4] - Accounts receivable financing increased by 55.40% compared to the beginning of the period, mainly due to an increase in AAA-rated bills[30] - Other income increased by 221.52% year-on-year, primarily due to an increase in government subsidies received during the period[33] - Minority interests decreased by 99.02% compared to the beginning of the period, mainly due to the net loss of the controlling subsidiary during the period[32] - Minority interest loss decreased by 398.18% year-on-year, primarily due to a decrease in net profit of the controlling subsidiary[46] - Other current assets increased by 78.14% compared to the beginning of the period, mainly due to an increase in deductible input tax[43] - Accounts receivable decreased by 86.03% compared to the beginning of the period, mainly due to a reduction in non-AAA rated notes[42] - Accounts payable decreased by 72.85% compared to the beginning of the period, primarily due to a reduction in note settlement business[44]

Production Capacity and Product Development - The company is expanding its heparin raw material production capacity by 35 tons to address capacity bottlenecks and enhance net profit margins from heparin raw materials[7]. - The company is actively promoting the bulk export and international registration of non-pig heparin products[8]. - The company has developed advanced biochemical technologies that significantly improve product yield and reduce production cycles, achieving standards higher than industry norms[2]. - The company plans to expand its raw material drug production capacity and actively promote innovative drug research and development[147]. - The company is actively developing non-pig source low molecular weight heparin, with successful HALAL certification for bovine heparin sodium products in Indonesia and Malaysia[155]. - The company is advancing the clinical trials for Abenatide injection, with all subjects enrolled by January 2022, and is progressing with two anti-tumor targeted new drugs in preclinical research[154]. - The company’s research institute focuses on expanding its heparin product line, polysaccharide and peptide products, and developing anti-tumor drugs, with increased investment in R&D planned for the coming years[172]. Financial Performance - The company achieved operating revenue of CNY 2,336.23 million in 2022, a decrease of 21.29% compared to the previous year[129]. - The net profit attributable to shareholders was CNY 17.51 million, representing a decline of 92.50% year-on-year[147]. - Domestic sales accounted for 72.94% of total revenue, while international sales contributed 27.06%, with international sales decreasing by 37.49%[129]. - The gross profit margin for the biopharmaceutical sector was 45.71%, down 13.44% from the previous year[130]. - Revenue from low molecular weight heparin preparations dropped by 27.55% to $1,205,645,412.90, representing 51.61% of total revenue[187]. - Revenue from ordinary heparin raw materials was $596,724,641.10, accounting for 25.54% of total revenue, down 13.78%[187]. - The revenue from ordinary heparin preparations surged by 196.24% to $35,517,662.19, making up 1.52% of total revenue[187]. - Other revenue sources contributed $63,319,199.97, which is 2.71% of total revenue, down 19.86% year-over-year[187]. Corporate Governance and Internal Control - The company maintains a strong commitment to corporate governance, ensuring compliance with relevant laws and regulations[13]. - The company emphasizes talent development and has established a drug research institute to ensure continuous technological innovation[4]. - The company is optimizing its internal control system to mitigate management risks and enhance operational efficiency[10]. - The independent directors provided impartial opinions on the annual profit distribution plan and external guarantees during the reporting period[35]. - The company has maintained a risk-oriented approach in its internal control supervision activities, with no significant issues reported during the period[37]. - The company has not encountered any significant internal control deficiencies in financial reporting during the reporting period[96]. - The company has a complete mechanism for determining the remuneration of directors and senior management based on performance and capability assessments[63]. Environmental Compliance - The company has completed environmental impact assessments for multiple projects, including a series of polysaccharide and protein peptide products[79]. - The company has obtained pollution discharge permits valid until 2026 for its subsidiaries, ensuring compliance with environmental regulations[81]. - The company has implemented a self-monitoring plan for environmental compliance, with all monitoring results meeting the relevant discharge standards[91]. - The wastewater treatment facility processed a total of 42,410.52 tons of wastewater in 2022, with no instances of exceeding discharge standards[87]. - The company’s air pollution control systems, including a chemical deodorization system and a biological deodorization system, operated normally throughout the year, meeting emission standards[111]. - The company has invested approximately CNY 1 million in environmental governance and protection in 2022[119]. - The company has a compensation limit of CNY 3 million for its environmental pollution liability insurance, effective from July 23, 2022, to July 22, 2023[122]. - The company has not reported any penalties or rectification measures during the reporting period[195]. Market Strategy and Sales - The company has established a mature domestic and international marketing network, reducing dependency on any single market[4]. - The company is adjusting its product and customer structure to adapt to market changes, aiming for higher sales revenue[7]. - The company has a complete and independent production and sales system, allowing for autonomous decision-making and contract signing[50]. - The company has continuously improved its internal control system to adapt to changing external environments and internal management requirements[44]. - The company has established a unique competitive advantage in the industry through 20 years of efforts in supply chain management, quality control, international market layout, and independent innovation, ensuring sustainable growth in performance[168]. Shareholder Communication and Dividends - The company proposed a cash dividend of RMB 0.26 per 10 shares (including tax) based on the total share capital after deducting shares in the repurchase account[40]. - The company has not engaged in any investor communication activities during the reporting period[11]. - The company’s profit distribution plan complies with relevant regulations and the company’s articles of association[41]. - The company has a clear and transparent cash dividend policy that aligns with its articles of association and shareholder resolutions[71]. - The company has not proposed a cash dividend distribution plan despite having positive distributable profits for the parent company during the reporting period[72]. Legal Matters - The company has received four lawsuits related to false securities statements in 2022, with one case still under trial, while two claims were dismissed[185]. - There were no related party transactions involving asset or equity acquisitions or sales during the reporting period[196]. - The company did not engage in any related party debt or equity transactions during the reporting period[198]. - There were no significant contracts that contributed to over 10% of the total profit during the reporting period[190].

证券代码：300255 证券简称：常山药业 编号：2014-2 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|----------------------------------------|------------------------------------|----------------------------------------------------|--------| | | √ 特定对象调研 | □ 分析师会议 | | | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | | | 类别 | □ 新闻发布会 | □ 路演活动 | | | | | □ 现场参观 | | | | | | □ 其他 | （请文字说明其他活动内容） | | | | | 天安财产保险 | 党新星 | 北京大君智萌 | 李红 | | 参与单位名称及 | 北京大君智萌 | 庄伟 | 北京大君智萌 | 杨永清 | | 人员姓名 | 民生证券 | 张金洋 | 深圳裕晋投资 | 许杰 | | ...